Cannabis’s Promise: The Latest Medical Research
Cannabis has been consumed for thousands of years, and many have long recognized its medical and therapeutic benefits. While the U.S. government continues to classify it as a federally illegal, Schedule I drug with “no accepted medical use and a high potential for abuse,” nearly 40 states have approved the plant for medical use, and 20 have adult-use sales programs in place.
Because of its Schedule I status, medical research has been limited and restricted. However, there are companies that have made significant headway, developing formulations to treat everything from chronic pain to Parkinson’s disease to pulmonary inflammation, and are working toward U.S. Food and Drug Administration-approved human trials so that patients can have access to cannabis-based treatments.
Cannabis Business Times and Cannabis Conference -- the leading media brand and event known for providing the most up-to-date, research-based and vetted information on cannabis cultivation and plant science -- are offering in-depth sessions at Cannabis Conference from researchers who will share their latest work to not only provide critical medicine to improve wellness and quality of life, but to bridge the medical and cannabis communities together and eradicate cannabis’s stigma once and for all.
Note: These sessions are accessible to conference registrants with any pass type, including Expo Only.
Cannabis’s Promise: The Latest Medical Research Agenda
| Wednesday, August 16, 2023 | |
|---|---|
| 10:30 AM – 11:15 AM | New Research Supports Cannabinoid-Based Treatments for Parkinson's Disease, Chronic Pain, Inflammation, and More Cannabis medical research has long been limited and more difficult to perform because of its federally illegal status. In the federal government’s eyes, cannabis is a Schedule I drug, on par with heroin, with no medical benefit. Gb Sciences, a plant-based research and biopharmaceutical drug development company, has been working to change that by getting U.S. Food and Drug Administration (U.S. FDA) approval for human trials on prescription drug formulations to treat specific ailments. Dr. Andrea Small-Howard, president and chief science officer at Gb Sciences, says this work is an important step in demonstrating medical value, which helps with the destigmatization of cannabis. Dr. Small-Howard will discuss the company’s journey and latest research validating the efficacy of different cannabinoid-containing formulations designed for the treatment of Parkinson's disease, chronic pain, and inflammation. Speaker: Dr. Andrea Small-Howard, President and Chief Science Officer, GB Sciences |
| 11:30 AM – 12:30 PM | The Path to Prescription: One Company's Journey to Bring a Cannabinoid-Based Treatment to Market In order to bring an FDA-approved drug to market, companies must clear the highest bars for approval, and it requires years of dedication, research, not to mention millions of dollars in funding. Cannabinoids biopharma company RS BioTherapeutics, Inc. has formulated a first-in-class alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation, including COPD, Asthma, Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Cystic Fibrosis. Dr. Michelle L. Shuffett, Senior Vice President of Medical and Scientific Affairs for RS BioTherapeutics, will share the company's journey to developing its novel cannabinoid-based treatment, RSBT-001, including what inspired the company to explore anti-inflammatory properties of cannabinoids, what makes the patent-pending formulation unique, steps required to get animal and human trials approved, what the findings have shown so far, and the timeline and costs expected to finally deliver the prescription to patients. She'll also share partnerships required to produce the treatment, and where there might be opportunities for cultivation companies to work with pharmaceutical companies in the future, and the cultivation and quality parameters necessary to create pharmaceutical-grade products. Dr. Shuffett will also share why clinical trials with cannabinoid-based medicines demonstrating the positive benefits of the plant are crucial to promote more widespread acceptance of cannabis, especially among the physician community. Speaker: Dr. Michelle L. Shuffett, Senior Vice President of Medical and Scientific Affairs, RS BioTherapeutics |
*Note: These sessions will not be recorded; video access of these sessions is not included in the All-Access pass.